Pfizer Inc said on Wednesday it had started the real-time submission of its application seeking Health Canada’s approval of its oral COVID-19 antiviral drug candidate.
The pill, PF-07321332, is designed to block a key enzyme needed for the coronavirus to multiply.
The move comes after the Canadian government announced on Tuesday that it was in advanced talks with Pfizer and Merck & Co Inc regarding a purchase agreement for their COVID-19 antiviral drugs, as the country attempts to control the spread of the Omicron coronavirus variant.
The country has identified seven people with the new variant as of Nov. 30.
Get weekly health news
The drugmaker last month submitted its application seeking U.S. authorization of the experimental pill, which was shown to cut the chance of hospitalization or death for adults at risk of severe disease by 89 per cent in a clinical trial.
- Why Canadian beer cans are ‘almost impossible’ as tariffs near 1-year mark
- Latest alleged Iranian regime official found in Canada wants his identity hidden
- Jivani’s trip to Washington has some Conservative MPs scratching their heads
- Semi driver who caused Humboldt Broncos bus crash loses refugee bid
-
![]()
Truck driver who caused Humboldt Broncos bus crash loses bid to stay in Canada as refugee -
![]()
Carney cancels EV mandate, announces buyer incentives in Canada’s new auto strategy -
![]()
Canada to open new consulate in Greenland capital amid uncertainty in Arctic -
![]()
Canada at the Olympics: A look back at a century of moments
Comments